Related references
Note: Only part of the references are listed.Protective effect and mechanism of loganin and morroniside on acute lung injury and pulmonary fibrosis
Lianghua Chen et al.
PHYTOMEDICINE (2022)
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
Anne Montfort et al.
CLINICAL CANCER RESEARCH (2021)
The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
Dan-in Jang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
TNF in the era of immune checkpoint inhibitors: friend or foe?
Allen Y. Chen et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Jee Hye Kang et al.
TRENDS IN IMMUNOLOGY (2021)
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review
Wang Xie et al.
FRONTIERS IN IMMUNOLOGY (2021)
CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice
Yoshinori Yasuda et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Pulmonary myeloid cell uptake of biodegradable nanoparticles conjugated with an anti-fibrotic agent provides a novel strategy for treating chronic allergic airways disease
Amlan Chakraborty et al.
BIOMATERIALS (2021)
A novel humanized model of rheumatoid arthritis associated lung disease
Li Lin et al.
CLINICAL IMMUNOLOGY (2021)
Iguratimod reduces B-cell secretion of immunoglobulin to play a protective role in interstitial lung disease
Qing Han et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
T-Cell-Derived miRNA-214 Mediates Perivascular Fibrosis in Hypertension
Ryszard Nosalski et al.
CIRCULATION RESEARCH (2020)
Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-α siRNA with PAMAM dendrimers in a murine model
Adam Bohr et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Daniel Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events
Jarushka Naidoo et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
Audrey Simonaggio et al.
JAMA ONCOLOGY (2019)
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Yousef R. Badran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
Patrick Arnaud-Coffin et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
Xuexiang Du et al.
CELL RESEARCH (2018)
TNF activity and T cells
Amit K. Mehta et al.
CYTOKINE (2018)
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
Yinghong Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial
Merel J. l'Ami et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study
Marie Kostine et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis
Walter P. Maksymowych et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Laura C. Cappelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Florie Bertrand et al.
NATURE COMMUNICATIONS (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
George D. Kalliolias et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Harnessing the immune system to improve cancer therapy
Nikos E. Papaioannou et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Blocking Tumor Necrosis Factor a Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma
Florie Bertrand et al.
CANCER RESEARCH (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Anti-TNF therapy: past, present and future
Claudia Monaco et al.
INTERNATIONAL IMMUNOLOGY (2015)
Anti-TNF in rheumatoid arthritis: an overview
Helga Radner et al.
WIENER MEDIZINISCHE WOCHENSCHRIFT (2015)
The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis
Jeffery M. Cowden et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Potential use of TNF-α inhibitors in systemic sclerosis
Giuseppe Murdaca et al.
IMMUNOTHERAPY (2014)
Periodontal and Serum Protein Profiles in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitor Adalimumab
Tetsuo Kobayashi et al.
JOURNAL OF PERIODONTOLOGY (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Association between anti-TNF-α therapy and interstitial lung disease
Lisa J. Herrinton et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms
Wataru Ise et al.
NATURE IMMUNOLOGY (2010)
Standardized quantification of pulmonary fibrosis in histological samples
Ralf-Harto Huebner et al.
BIOTECHNIQUES (2008)
Structural mechanisms of costimulation
JCD Schwartz et al.
NATURE IMMUNOLOGY (2002)
Share Paper
